Conference report: AAPS and US FDA Crystal City V meeting on Quantitative Bioanalytical Method Validation and Implementation: feedback from the EBF.
Crystal City V meeting on Quantitative Bioanalytical Method Validation and Implementation: 2013 Revised US FDA Guidance 3-5 December 2013, Hilton Baltimore, MD, USA The meeting provided an opportunity for Industry and regulators from the US FDA to discuss the recently published revised draft FDA Guidance for Industry on Bioanalytical Methods Validation during the 90 day review period. Key perspective and philosophical positions were shared leading to a healthy exchange of views and ideas on topics in the revised document. Discussions covered all aspects of bioanalytical method validation and method utilization. However, the main dialogue was focused on chromatographic methods, ligand-binding assay methods and biomarker analysis. The resulting open debate led to greater understanding of the document, but also provided clear feedback, including the request on harmonization with approved Bioanalytical Methods Validation guidance's release from other health authorities, as well as the consensus view between industry and the FDA. Members of the European Bioanalysis Forum summarized prospective discussions during the meeting in Baltimore; however, this Report is not intended to constitute the official proceedings from the meeting, which are expected to be published later this year.
UCB Pharma SA, Braine-l'Alleud, Belgium.
John
J
Smeraglia
Stuart
S
McDougall
Karen
K
Elsby
Arjen
A
Companjen
Stephen
S
White
Michaela
M
Golob
Margarete
M
Brudny-Kloeppel
Peter van
Pv
Amsterdam
Philip
P
Timmerman
D001681:Biological Assay / Q000379:methods*; D002845:Chromatography; D033161:Government Regulation; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration; D054928:Validation Studies as Topic